OTC: BRCTF - BioArctic AB (publ)

Yield per half year: +41.7%
Dividend yield: 0.00%
Sector: Healthcare

Share chart BioArctic AB (publ)

Extended chart Simple chart
Financial Markets by TradingView

About BioArctic AB (publ)

BioArctic AB (publ) develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. It also develops ABBV-0805, for treating Parkinson's disease.

more details
In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders. Further, it develops BAN1503, AD-BT2802, AD-BT2803, AD1502, AD1503, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814 andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, BAN0805, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета sek
Сайт https://www.bioarctic.se
Цена ао 23.02
Change price per day: 0% (22.608)
Change price per week: -6.77% (24.25)
Change price per month: +12.96% (20.015)
Change price per 3 month: +31.25% (17.2255)
Change price per half year: +41.7% (15.955)
Change price per year: +6.39% (21.25)
Change price per 3 year: 0% (22.608)
Change price per 5 year: 0% (22.608)
Change price per 10 year: 0% (22.608)
Change price per year to date: +23.54% (18.3)
All parameters

Underestimation

Title Value Grade
P/S 69.53 1
P/BV 19.99 1
P/E 99.75 1
EV/EBITDA -92.9 0
Total: 1.13

Efficiency

Title Value Grade
ROA, % -15.41 0
ROE, % -18.24 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 1.17

Debt

Title Value Grade
Debt/EBITDA -0.289 10
Total: 9

Growth impulse

Title Value Grade
Yield Revenue, % 312.77 10
Yield Ebitda, % 151.96 10
Yield EPS, % 160.36 10
Total: 10
More

Institutions Volume Share, %
Vanguard International Stock Index-Total Intl Stock Indx 453678 0.62
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 266229 0.36
iShares Core MSCI EAFE ETF 202146 0.27
iShares MSCI EAFE Small Cap ETF 146626 0.2
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index 120035 0.16
Vanguard International Stock Index-Vanguard European Stock Index 68937 0.09
Schwab Strategic Tr-Schwab International Small Cap Equity ETF 66133 0.09
iShares Core MSCI Total International Stock ETF 50841 0.07
DFA International Core Equity Portfolio 42578 0.06
College Retirement Equities Fund-Stock Account 30598 0.04



Head Job title Payment Year of birth
Dr. Gunilla Osswald Ph.D. President & CEO 8.2M 1961 (64 years)
Dr. Pär Gellerfors Co-Founder, Senior VP of Business Strategy & Director 321k 1947 (78 years)
Prof. Lars Lannfelt Co-Founder, Senior VP of Medical science & Director 2.45M 1949 (76 years)
Mr. Anders Martin-Lof M.B.A., M.Sc. Chief Financial Officer N/A 1971 (54 years)
Mr. Christer Möller VP of Pre-Clinical Development & Chief Scientific Officer N/A 1959 (66 years)
Mr. Oskar Bosson VP and Head of IR & Communication N/A 1976 (49 years)
Mr. Leif Gallo LL.M. General Counsel and Head of Legal & IP N/A 1959 (66 years)
Mr. Harald Borgeke Head of Public Affairs N/A
Ms. Frida Lekander Head of Marketing N/A
Ms. Johanna Fälting Chief Research Officer & Head of Research 1972 (53 years)

Address: Sweden, Stockholm, Warfvinges vag 35 - open in Google maps, open in Yandex maps
Website: https://www.bioarctic.se